Menu Search
Equities

EGF Theramed Health Corp

  • Add to watchlist
  • Add to portfolio
  • Add an alert
AUH:MUN

EGF Theramed Health Corp

Actions
  • Price (EUR)0.0635
  • Today's Change0.00 / 0.00%
  • Shares traded200.00
  • 1 Year change-35.53%
  • Beta0.4230
Data delayed at least 15 minutes, as of Feb 17 2026 07:35 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

EGF Theramed Health Corp. is a Canada-based company engaged in developing products, technologies, and diagnostic tools focused on personalized medical care, including research into natural health and wellness products. The Company is focused on the psilocybin space, looking at methods of improving delivery systems for the compound. The Company explores many other medical areas, including weight loss, skin care and heart disease. Its portfolio includes Pharmadelic Labs and Green Parrot Labs. Pharmadelic Labs is a biotech company focusing on improving and patenting engineering processes for the biosynthesis of compounds - primarily psilocybin, the psychoactive component of magic mushrooms. Green Parrot Labs is a Caribbean-based company focusing on research into psilocybin and establishing health centers dealing with treatment-resistant conditions. The Company is also actively exploring opportunities in all medical areas in domestic and international markets.

  • Revenue in CAD (TTM)0.00
  • Net income in CAD-3.22m
  • Incorporated2011
  • Employees--
  • Location
    EGF Theramed Health CorpSuite 1600 - 609 Granville StreetPacific CentreP.O. Box 10068VANCOUVER V7Y 1C3CanadaCAN
  • Phone+1 (604) 780-3311
  • Fax+1 (604) 780-3311
  • Websitehttps://www.egftheramedhealth.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.